Nubeqa

Active Ingredient(s): Darolutamide
FDA Approved: * July 30, 2019
Pharm Company: * BAYER HEALTHCARE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Nubeqa Overview

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of prostate cancer in men.[1][3][4][5] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration.[1][3] The medication is taken by mouth twice per day with food.[1] Side effects of daro...

Read more Nubeqa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Darolutamide

Recent Nubeqa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Darolutamide
  • Tablet: 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nubeqa: (1 result)

Sorted by National Drug Code
  • 50419-395 Nubeqa 300 mg Oral Tablet, Film Coated by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Darolutamide or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 11 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA